A new predictive model warns that metabolic dysfunction-associated steatotic liver disease (MASLD) will see a dramatic rise in the U.S., with cases increasing from 33.7% of adults in 2020 to 41.4% by 2050. This translates to 122 million Americans living with MASLD, making it a growing public health crisis.
Key Projections:
- MASH cases (severe liver disease with fibrosis) to rise from 14.9M (5.8%) to 23.2M (7.9%)
- Decompensated cirrhosis cases will triple, reaching 1M by 2050